Oncocyte corp (OCX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
REVENUE
Total revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

TOTAL COSTS AND OPERATING EXPENSES
Cost of revenues

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

7,610

6,794

5,680

5,582

6,396

6,514

6,817

7,126

6,801

7,174

7,097

6,624

5,822

5,677

5,677

5,408

5,099

4,527

0

0

0

General and administrative

15,457

13,281

11,660

9,970

7,669

7,007

6,219

9,196

8,976

9,232

8,567

5,341

5,293

4,265

4,931

5,180

4,632

3,867

0

0

0

Sales and marketing

3,449

2,164

1,423

977

1,228

1,681

2,012

2,538

2,446

2,443

2,386

1,832

1,625

1,198

0

0

0

-

-

-

-

Total costs and operating expenses

26,689

22,239

18,763

16,529

15,293

15,202

15,048

18,860

18,223

18,849

18,050

13,797

12,740

11,140

11,586

11,410

10,283

8,718

0

0

0

Loss from operations

-26,673

-22,239

-18,763

-16,529

-15,293

-15,202

-15,048

-18,860

-18,223

-18,849

-18,050

-13,797

-12,740

-11,140

-11,586

-11,410

-10,283

-8,718

0

0

0

OTHER INCOME (EXPENSES), NET
Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Interest expense, net

296

299

233

48

-175

-216

-234

-255

-264

-217

0

0

0

-

-

-

-

-

0

0

0

Unrealized gain (loss) on marketable equity securities

-280

-49

-509

-304

-439

-427

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Pro rata loss from equity method investment in Razor

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on sale of available-for-sale securities and other expenses, net

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

Other income (expenses), net

31

-3

70

68

67

91

0

0

0

-

-

-

-159

0

-25

0

0

-

0

-

-

Total other income (expenses), net

-716

-187

-209

-189

-547

-552

-167

-290

-226

-526

-466

-408

-204

-28

-19

-16

-11

-17

0

0

0

LOSS BEFORE INCOME TAXES

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET LOSS

-26,294

-22,426

-18,972

-16,718

-15,840

-15,754

-15,215

-19,150

-18,449

-19,375

-18,516

-14,205

-12,944

-11,168

-11,605

-11,426

-10,294

-8,735

0

0

0

Net loss per share; basic and diluted

-0.13

-0.16

-0.10

-0.10

-0.08

-0.11

-0.07

-0.12

-0.12

-0.13

-0.22

-0.13

-0.16

-0.10

-0.10

-0.10

-0.12

-0.15

-0.12

-0.07

-0.08

Weighted average shares outstanding; basic and diluted

61

101,191

51,973

51,973

46

40,789

40,227

38,708

31,676

62,386

30

29,398

28,965

28,733

26,560

25,427

25,396

23,666

20,970

21,200

18,200